Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Last updated: February 11, 2026 00:20

By

3 Min Read

Summarize with AI

Hangzhou Tangji Medical Technology Co., Ltd. has filed its IPO prospectus with the Hong Kong Stock Exchange, targeting a main board listing to capitalize on its position as China’s pioneer in endoscopic obesity treatment. The company’s flagship Gastric Bypass Stent System (GBS), first approved by NMPA in January 2024 as a Class III innovative medical device, offers a minimally invasive alternative to bariatric surgery for weight loss and metabolic disease management.

Contents

Transaction Overview
Flagship Product: Gastric Bypass Stent System (GBS)
Market Context & Strategic Positioning
Pipeline & Comprehensive Cycle Management
Competitive Landscape

- Advertisement -

Transaction Overview

Element	Detail
Company	Hangzhou Tangji Medical Technology Co., Ltd.
Listing Venue	Hong Kong Stock Exchange (Main Board)
Filing Date	Week of 09 Feb 2026
Founded	2016
Sector	Medical devices – obesity and metabolic disease
Use of Proceeds	Expected to fund commercialization, R&D pipeline, and manufacturing scale-up

Flagship Product: Gastric Bypass Stent System (GBS)

Feature	GBS Specification	Clinical Value
Design Inspiration	Roux-en-Y Gastric Bypass (RYGB) surgery	Mimics metabolic benefits of gold-standard bariatric procedure
Delivery	Endoscopic, minimally invasive	No abdominal incisions; reduced recovery time vs. surgery
Regulatory Status	Class III innovative medical device (NMPA, Jan 2024)	First device in China approved for endoscopic obesity treatment
Mechanism	Stent-based gastric bypass simulation	Restricts food intake and alters nutrient absorption pathways
Target Population	Obese patients (BMI ≥28) with metabolic comorbidities	Bridge between lifestyle intervention and invasive surgery

Market Context & Strategic Positioning

Factor	Market Implication
China Obesity Epidemic	>50% of adults overweight/obese; 120 million with BMI ≥28; bariatric surgery penetration <1% due to invasiveness and cost
Endoscopic Bariatrics Gap	No approved devices prior to GBS; massive unmet need between drugs (GLP-1 shortages) and surgery
GLP-1 Synergy/Competition	GBS offers procedural alternative to semaglutide/tirzepatide for patients seeking durable non-pharmacological solution
Innovative Device Premium	Class III designation enables NRDL negotiation priority and hospital procurement preference under China’s medical device localization policy

Pipeline & Comprehensive Cycle Management

Strategic Focus	Execution Plan
GBS Commercialization	Scale manufacturing; train endoscopists in tier-1/2 hospitals; establish reimbursement pathway
Product Line Expansion	Adjunctive devices for stent management, metabolic monitoring, and patient compliance
Digital Health Integration	Comprehensive cycle management platform combining device data with lifestyle coaching
Global Expansion	CE Mark and FDA regulatory pathway initiation post-HK listing

Competitor	Product	Status	Tangji Differentiation
ValenTx	Endoscopic bypass sleeve (US/EU)	CE Mark; not in China	GBS first-mover China advantage; tailored to Asian anatomy
EndoBarrier	Duodenal-jejunal bypass liner	Limited commercial traction	GBS mimics RYGB more closely; superior metabolic outcomes
GI Dynamics	EndoBarrier variant	Financial distress	Tangji stronger balance sheet post-IPO; NMPA regulatory credibility

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Transaction Overview

Flagship Product: Gastric Bypass Stent System (GBS)

Market Context & Strategic Positioning

Pipeline & Comprehensive Cycle Management

Competitive Landscape

You May also Like

Junshi Biosciences roconkibart psoriasis NMPA Acceptance

Merck & Co.’s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan

J&J Reports Strong Q3 2023 Sales Growth Amid Diverse Business Performance

Zhonghong Pulin Partners with Shanghai Pharma for Logistics and Distribution

About Company